|
| Index | - | P/E | - | EPS (ttm) | -0.62 | Insider Own | 3.60% | Shs Outstand | 92.76M | Perf Week | -15.00% |
| Market Cap | 100.43M | Forward P/E | - | EPS next Y | -0.46 | Insider Trans | 0.00% | Shs Float | 48.45M | Perf Month | -23.31% |
| Income | -53.00M | PEG | - | EPS next Q | -0.16 | Inst Own | 49.90% | Short Float / Ratio | 0.29% / 2.57 | Perf Quarter | -19.05% |
| Sales | 42.80M | P/S | 2.35 | EPS this Y | 6.30% | Inst Trans | 50.27% | Short Interest | 0.14M | Perf Half Y | -63.04% |
| Book/sh | 0.74 | P/B | 1.45 | EPS next Y | 16.40% | ROA | -37.30% | Target Price | 3.68 | Perf Year | -49.25% |
| Cash/sh | 0.64 | P/C | 1.68 | EPS next 5Y | - | ROE | -77.70% | 52W Range | 0.99 - 2.99 | Perf YTD | -8.93% |
| Dividend | - | P/FCF | - | EPS past 5Y | -8.50% | ROI | -67.60% | 52W High | -65.89% | Beta | 1.08 |
| Dividend % | - | Quick Ratio | 3.30 | Sales past 5Y | -39.60% | Gross Margin | 81.30% | 52W Low | 3.03% | ATR | 0.12 |
| Employees | 156 | Current Ratio | 3.30 | Sales Q/Q | 354.50% | Oper. Margin | - | RSI (14) | 38.46 | Volatility | 16.79% 9.07% |
| Optionable | Yes | Debt/Eq | 0.82 | EPS Q/Q | 62.80% | Profit Margin | - | Rel Volume | 1.96 | Prev Close | 1.07 |
| Shortable | Yes | LT Debt/Eq | 0.82 | Earnings | Mar 20 BMO | Payout | - | Avg Volume | 55.59K | Price | 1.02 |
| Recom | 2.20 | SMA20 | -14.79% | SMA50 | -16.75% | SMA200 | -35.39% | Volume | 12,610 | Change | -4.67% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite